Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer

Inclusion Criteria: * 18-75 years old (including 18 and 75 years old); * Eastern Cooperation Oncology Group (ECOG) performance status of 0-1; * Pathologically determined gastric or gastroesophageal junction adenocarcinoma; * Advanced patients with radiographic confirmation of inoperable complete resection; * No previous anti-tumor treatment for metastatic diseases; * At least one measurable lesion according to RECIST version 1.1; * Ability to take medications orally; * No active bleeding; * Adequate organ functions: Absolute neutrophil count ≥2×109/L; Platelet ≥100×109/L; Hemoglobin ≥90g/L; WBC≥4×109/L Total bilirubin ≤ 1.5XULN; ALT and AST ≤2.5XULN ； Serum creatinine (Cr) ≤1.5XULN； • Have fully understood the study and voluntarily signed the informed consent; Exclusion Criteria: * Patients who had received any drug in the study protocol in the last year; * Deficient mismatch repair (dMMR) or MSI-H detected by genetic test; * HER2 positive（HER-2 3+, or HER-2 2+ and FISH+）; * Hypertension that could not be controlled by drugs before enrollment was defined as: systolic blood pressure ≥150 mmHg and/or diastolic blood pressure ≥90 mmHg; * Patients with acute coronary syndromes (including myocardial infarction and unstable angina) received coronary angioplasty or stenting within 6 months before enrollment; * Patients with massive pleural or peritoneal effusion requiring drainage; * Patients with severe ECG abnormalities or heart diseases (such as cardiac insufficiency, myocar…